Luveltamab Tazevibulin Shows Encouraging Activity in Frα-Selected Advanced Ovarian Cancer
January 16, 2023 10:07 amby Caroline Seymour
Treatment with the folate receptor α–directed antibody-drug conjugate luveltamab tazevibulin led to a 37.5% overall response rate in Frα-selected patients with advanced ovarian cancer, defined by a tumor proportion score above 25%.
Treatment with the folate receptor